Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis

9 Dec 2011

Abstract excerpt

Myc is an oncogenic transcription factor frequently dysregulated in human cancer. To identify pathways supporting the Myc oncogenic program, we used a genome-wide RNA interference screen to search for Myc-synthetic lethal genes and uncovered a role for the SUMO-activating enzyme (SAE1/2). Loss of SAE1/2 enzymatic activity drives synthetic lethality with Myc. Inactivation of SAE2 leads to mitotic catastrophe and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to Peptidase Inhibition and Analysis
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22157079
DOI: 10.1126/science.1212728

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven TumorigenesisPMID 22157079Read ↗

Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphomaSemantic proximity Read ↗

Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage.Semantic proximity Read ↗

SUMO2 Inhibition Reverses Aberrant Epigenetic Rewiring Driven by Synovial Sarcoma Fusion Oncoproteins and Impairs SarcomagenesisSemantic proximity Read ↗

Writing and erasing MYC ubiquitination and SUMOylationSemantic proximity Read ↗

Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation.Semantic proximity Read ↗

Functional genomics identifies therapeutic targets for MYC-driven cancerSemantic proximity Read ↗

Targeting SUMO Signaling to Wrestle CancerSemantic proximity Read ↗

Synthetic lethal screens as a means to understand and treat MYC-driven cancers.Semantic proximity Read ↗

Therapeutic Potential of Targeting the SUMO Pathway in CancerSemantic proximity Read ↗

Synthetic inhibition of the SUMO pathway by targeting the SAE1 component via TAK-981 compound impairs tumor growth and chemosensitizers embryonal and alveolar rhabdomyosarcoma cell linesSemantic proximity Read ↗

MYC Deregulation in Primary Human CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.